Trial Profile
A Randomized, Controlled, Parallel Group, Patient-blinded, Single-center, Phase I Pilot Study to Assess Tolerability and Safety of Repeated Subcutaneous Administration of Two Doses of AFFITOPE PD01A Formulated With Adjuvant to Patients With Parkinson's Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Affitope PD01 (Primary) ; Aluminium oxide
- Indications Parkinson's disease
- Focus Adverse reactions; Biomarker; First in man
- Sponsors AFFiRiS
- 16 Sep 2020 Results presented at the 24th International Congress of Parkinson's Disease and Movement Disorders
- 31 Jul 2014 Results published in an AFFiRiS media release.
- 31 Jul 2014 Primary endpoint (Tolerability/Safety) has been met, according to an AFFiRiS media release.